news
Phase III study of avelumab in NSCLC starts
4 November 2015 | By Victoria White
Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody that potentially uses the body’s own immune system to fight cancer...
List view / Grid view
Merck KGaA
news
FDA grants Fast Track designation to avelumab for Merkel cell carcinoma
8 October 2015 | By Victoria White
The designation relates to the clinical development programme for avelumab in metastatic MCC, which includes the Phase II study, JAVELIN Merkel 200...
news
FDA Fast Track designation for evofosfamide for treatment of patients living with advanced pancreatic cancer
12 May 2015 | By Victoria White
The FDA has granted Fast Track designation for the development of evofosfamide for the treatment of patients with advanced pancreatic cancer...
news
Merck KGaA and Pfizer initiate Phase III study with avelumab in patients with stage IIIb/IV non-small cell lung cancer
21 April 2015 | By Victoria White
Merck KGaA and Pfizer have announced the initiation and first patient treated in the Phase III study of avelumab compared with docetaxel, in patients NSCLC...
news
Merck supports schistosomiasis education in Mozambique
23 March 2015 | By Victoria White
Merck is fighting schistosomiasis in Mozambique, providing WHO with praziquantel tablets free of charge and presenting 20,000 educational brochures...
news
Ethiopia will receive 13 million praziquantel tablets in 2015
12 December 2014 | By Merck KGaA
Merck supports the World Health Organization (WHO) to fight the parasitic worm disease schistosomiasis in Africa...
news
Merck KGaA to acquire Sigma-Aldrich to enhance position in attractive life science industry
24 September 2014 | By Sigma-Aldrich
Merck KGaA , a leading company for innovative and top-quality high-tech products in the pharmaceutical, chemical and life science sectors, and Sigma-Aldrich announced that they have entered into a definitive agreement under which Merck KGaA, Darmstadt, Germany, will acquire Sigma-Aldrich for $17.0 billion...
news
EMD Serono and Pfizer announce FDA approval of Rebif® Rebidose® (interferon beta-1a)
3 January 2013 | By EMD Serono; Pfizer Inc.
The majority of patients found Rebif Rebidose easy to use in a user trial...
news
Merck Millipore completes acquisition of Biotest AG’s microbiology business
1 August 2011 | By Merck KGaA
Merck Millipore has completed the acquisition of the microbiology business of Biotest AG...
news
EMD Millipore announces change in supply chain of insulin for cell culture media
25 January 2011 | By Novo Nordisk
EMD Millipore, announced an agreement with Novo Nordisk, to transfer the distribution of recombinant human insulin for cell culture media...
news
Merck KGaA and Lead Discovery Center Enter Collaboration for the Discovery of Anti-Cancer Compounds
20 January 2011 | By Merck Serono
Merck Serono, announced today that Merck KGaA has signed a cooperation agreement with the Lead Discovery Center GmbH (LDC)...
news
Erbitux Long-Term Survival Benefit for mCRC Patients Confirmed With FOLFOX
19 January 2011 | By Merck KGaA
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today highlighted a further analysis of the large randomized Phase II OPUSa study...
news
Domain Therapeutics and Merck Serono announce an agreement to develop drugs for Parkinson’s disease
17 January 2011 | By Andrew Lloyd & Associates
Agreement covers metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson's disease...
article
Interfacing LIMS with ELN
20 July 2006 | By Dr Jan Hauss, Laboratory Manager, Merck KGaA
Today, electronic support for scientific research from the bench to the product is reality. For many years there has been an organic growth of different electronic systems in various areas of industry. The current challenge is to combine these electronic islands to form solid ground for integrated cost efficient systems.…
article
Identification and prevalidation of safety biomarkers
24 March 2006 | By Michaela Kroeger, Merck KGaA, Institute of Toxicology, Matthias Glückmann, Applied Biosystems, Mass Spectrometry and Proteomics
To date, hazard/risk assessment of new drugs and chemicals primarily relies on the investigation of toxicological endpoints from animal studies. In this field, the full range of genomics and proteomics technologies can be used in efforts to uncover the molecular mechanisms at work in response to xenobiotic exposure. These new…
